24.44 USD
+0.53 (+2.22%)
At close: Feb 6, 2026
24.46 USD
+0.02 (+0.08%)
Pre-Market: 2/9/2026, 9:00:49 AM
Overall CPRX gets a fundamental rating of 8 out of 10. We evaluated CPRX against 523 industry peers in the Biotechnology industry. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. These ratings would make CPRX suitable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
- CPRX had positive earnings in the past year.
- In the past year CPRX had a positive cash flow from operations.
- CPRX had positive earnings in each of the past 5 years.
- CPRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- CPRX has a Return On Assets of 20.69%. This is amongst the best in the industry. CPRX outperforms 97.13% of its industry peers.
- CPRX's Return On Equity of 23.65% is amongst the best of the industry. CPRX outperforms 96.75% of its industry peers.
- CPRX has a Return On Invested Capital of 21.23%. This is amongst the best in the industry. CPRX outperforms 97.90% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for CPRX is above the industry average of 18.12%.
- The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
- CPRX has a Profit Margin of 37.64%. This is amongst the best in the industry. CPRX outperforms 96.75% of its industry peers.
- CPRX's Profit Margin has been stable in the last couple of years.
- CPRX's Operating Margin of 44.78% is amongst the best of the industry. CPRX outperforms 99.43% of its industry peers.
- In the last couple of years the Operating Margin of CPRX has grown nicely.
- With an excellent Gross Margin value of 85.68%, CPRX belongs to the best of the industry, outperforming 88.34% of the companies in the same industry.
- CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CPRX is still creating some value.
- CPRX has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for CPRX has been increased compared to 5 years ago.
- CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- CPRX has an Altman-Z score of 16.50. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
- CPRX's Altman-Z score of 16.50 is amongst the best of the industry. CPRX outperforms 87.57% of its industry peers.
- CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 16.5 |
ROIC/WACC1.71
WACC12.44%
2.3 Liquidity
- A Current Ratio of 6.62 indicates that CPRX has no problem at all paying its short term obligations.
- The Current ratio of CPRX (6.62) is better than 67.69% of its industry peers.
- A Quick Ratio of 6.40 indicates that CPRX has no problem at all paying its short term obligations.
- CPRX has a better Quick ratio (6.40) than 66.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
- CPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.76%, which is quite impressive.
- Measured over the past years, CPRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 34.29% on average per year.
- CPRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.56%.
- Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 36.89% on average per year.
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
- CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.80% yearly.
- CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.21% yearly.
EPS Next Y25.2%
EPS Next 2Y17.73%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue Next Year19.48%
Revenue Next 2Y13.05%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
3.3 Evolution
- The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- CPRX is valuated correctly with a Price/Earnings ratio of 14.21.
- Compared to the rest of the industry, the Price/Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 96.75% of the companies listed in the same industry.
- CPRX is valuated rather cheaply when we compare the Price/Earnings ratio to 27.93, which is the current average of the S&P500 Index.
- Based on the Price/Forward Earnings ratio of 13.46, the valuation of CPRX can be described as correct.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.13% of the companies listed in the same industry.
- CPRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.77, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.21 | ||
| Fwd PE | 13.46 |
4.2 Price Multiples
- CPRX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CPRX is cheaper than 98.47% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.71% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.8 | ||
| EV/EBITDA | 7.8 |
4.3 Compensation for Growth
- CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as CPRX's earnings are expected to grow with 12.53% in the coming years.
PEG (NY)0.56
PEG (5Y)0.41
EPS Next 2Y17.73%
EPS Next 3Y12.53%
5. Dividend
5.1 Amount
- CPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
24.44
+0.53 (+2.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners86.97%
Inst Owner Change-3.44%
Ins Owners5.48%
Ins Owner Change2.85%
Market Cap3.00B
Revenue(TTM)578.20M
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (43.99%)
Short Float %7.58%
Short Ratio7.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)16.56%
EPS beat(12)10
Avg EPS beat(12)13.3%
EPS beat(16)12
Avg EPS beat(16)8.79%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)0%
PT rev (3m)1.47%
EPS NQ rev (1m)9.09%
EPS NQ rev (3m)23.53%
EPS NY rev (1m)1.9%
EPS NY rev (3m)10.29%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)3.47%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)2.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.21 | ||
| Fwd PE | 13.46 | ||
| P/S | 5.2 | ||
| P/FCF | 12.8 | ||
| P/OCF | 12.79 | ||
| P/B | 3.26 | ||
| P/tB | 3.79 | ||
| EV/EBITDA | 7.8 |
EPS(TTM)1.72
EY7.04%
EPS(NY)1.82
Fwd EY7.43%
FCF(TTM)1.91
FCFY7.81%
OCF(TTM)1.91
OCFY7.82%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)0.56
PEG (5Y)0.41
Graham Number17.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROCE | 28.06% | ||
| ROIC | 21.23% | ||
| ROICexc | 84.1% | ||
| ROICexgc | 187.79% | ||
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% | ||
| FCFM | 40.59% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.31% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 593.88 | ||
| Cash Conversion | 79.12% | ||
| Profit Quality | 107.83% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 16.5 |
F-Score6
WACC12.44%
ROIC/WACC1.71
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y25.2%
EPS Next 2Y17.73%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year19.48%
Revenue Next 2Y13.05%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year76.08%
EBIT Next 3Y25.59%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status for CPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?
The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 25.2% in the next year.